Hemogenyx Pharmaceuticals plc
(“Hemogenyx Pharmaceuticals” or the “Company”)
LEI 2138008L93GYU5GN6179
Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company’s Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately 0.41 per cent of the Company’s issued share capital.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1. | Details of PDMR/person closely associated with them (“PCA”) | |||||
| a) | Name | Andrew Wright | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Financial Controller and Company Secretary | ||||
| b) | Initial notification/ amendment |
Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Full name of the entity | Hemogenyx Pharmaceuticals plc | ||||
| b) | Legal Entity Identifier code | 2138008L93GYU5GN6179 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of Hemogenyx Pharmaceuticals plc
GB00BYX3WZ24 |
||||
| b) | Nature of the transaction | Standalone acquisition of shares
|
||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information
– Aggregated volume – Price |
|
||||
| e) | Date of the transaction | 2022-05-27 | ||||
| f) | Place of the transaction | London Stock Exchange XLON |
||||
Enquiries:
| Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
| Peter Redmond, Director | peter.redmond@hemogenyx.com |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |